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Background: Topical nonsteroidal anti-inflammatory drug (NSAID) formulations, which 
produce less systemic exposure compared with oral formulations, are an option for the manage-
ment of osteoarthritis (OA). However, the overall safety and efficacy of these agents compared 
with oral or systemic therapy remains controversial.
Methods: Two 12-week, double-blind, double-dummy, randomized, controlled, multicenter 
studies compared the safety and efficacy profiles of diclofenac topical solution (TDiclo) with 
oral diclofenac (ODiclo). Each study independently showed that TDiclo had similar efficacy 
to ODiclo. To compare the safety profiles of TDiclo and ODiclo, a pooled safety analysis was 
performed for 927 total patients who had radiologically confirmed symptomatic OA of the 
knee. This pooled analysis included patients treated with TDiclo, containing 45.5% dimethyl 
sulfoxide (DMSO), and those treated with ODiclo. Safety assessments included monitoring of 
adverse events (AEs), recording of vital signs, dermatologic evaluation of the study knee, and 
clinical laboratory evaluation.
Results: AEs occurred in 312 (67.1%) patients using TDiclo versus 298 (64.5%) of those tak-
ing ODiclo. The most common AE with TDiclo was dry skin at the application site (24.1% vs 
1.9% with ODiclo; P , 0.0001). Fewer gastrointestinal (25.4% vs 39.0%; P , 0.0001) and 
cardiovascular (1.5% vs 3.5%; P = 0.055) AEs occurred with TDiclo compared with ODiclo. 
ODiclo was associated with significantly greater increases in liver enzymes and creatinine, and 
greater decreases in creatinine clearance and hemoglobin (P , 0.001 for all).
Conclusions: These findings suggest that TDiclo represents a useful alternative to oral NSAID 
therapy in the management of OA, with a more favorable safety profile.
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Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as diclofenac have an established 
place in the management of osteoarthritis (OA) and related inflammatory disorders.1–3 
While unable to modify the disease of OA, NSAIDs are frequently used chronically to 
manage symptoms. However, the gastrointestinal and cardiovascular risks associated 
with nonselective NSAIDs present challenges because OA predominantly affects older 
patients, who are inherently at greater risk for these events.4 Of particular concern are 
NSAID-related gastrointestinal adverse events (AEs), or "NSAID gastropathy", which 
result from decreased prostaglandin synthesis in the gastric lumen, and primarily 
affect older patients and women.3,5 NSAID gastropathy, which was first recognized 
in the medical literature in 1986, remains a serious complication for patients seeking 
relief of OA.6Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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A recent international, multicenter study of 3293 con-
secutive candidates for NSAID treatment of OA showed that 
86.6% were at increased gastrointestinal risk; 22.3% were 
considered at high risk for gastrointestinal events. The same 
study showed that 44.2% of patients were at high cardio-
vascular risk.4 In addition to increased gastrointestinal and 
cardiovascular risk, NSAIDs are associated with increased 
risk of hepatic and renal toxicity.7,8
One approach to addressing NSAID toxicity has been 
the development of topical formulations, which produce less 
systemic exposure to the drug than oral formulations;9 the 
use of such formulations is recommended in some current 
guidelines for the management of OA.1–3 Diclofenac topical 
solution (PENNSAID®, Mallinckrodt Inc, Hazelwood, MO) is 
a topical formulation of a 1.5% (w/w) solution of diclofenac 
sodium in a base containing 45.5% (w/w) dimethyl sulfoxide 
(DMSO) approved by the US Food and Drug Administration 
for treatment of the signs and symptoms of OA. The DMSO 
vehicle enhances the penetration of diclofenac through the 
skin compared with aqueous solutions.8
Several randomized clinical trials have shown that 
diclofenac topical solution with DMSO is effective and well 
tolerated in the treatment of OA.10–14 Two trials compared 
diclofenac topical solution with oral diclofenac for safety and 
effectiveness.13,14 Both studies evaluated efficacy using the 
pain and physical function subscales of the Western Ontario 
and McMaster Universities (WOMAC) Index. Tugwell et al 
utilized an additional co-primary endpoint, patient global 
assessment (PGA),13 whereas Simon et al assessed a patient 
overall health assessment (POHA).14 Details of the efficacy 
results from each study have been reported previously.13,14 
Because the 3 co-primary endpoints were assessed differently 
across the 2 trials, only the safety data from these trials were 
pooled and are presented here.
Methods
study design
Both studies were 12-week randomized, double-blind, double-
dummy, multicenter trials including patients with primary OA 
of the knee (Table 1).13,14 The study by Tugwell et al was pow-
ered to demonstrate equivalence between active treatments,13 
whereas a nonstatistical difference was determined in Simon 
et al through post hoc analysis.14 Detailed methodologies for 
both studies have been previously reported.13,14
Patients
In the study by Tugwell et al,13 eligible patients included 
individuals aged 40–85 years with primary OA of the knee 
defined as: 1) standard radiographic criteria for OA based on 
recent (within 3 months) examination,15 and 2) at least mild 
symptoms of OA based on minimum scores in predetermined 
subscales of the WOMAC Index assessment tool (pain, $125 mm; 
physical function, $425 mm)16 and PGA score $25 mm.
In the study by Simon et al,14 eligible patients were 
those aged 40–85 years with primary OA of the defined as   
1) standard radiographic criteria for OA based on recent   
(#3 months) examination, 2) pain with regular use of NSAID 
or other analgesic, and 3) flare of pain and minimum Lik-
ert pain score of 8 (40 on a scale normalized to 0–100) at 
baseline, following washout of previous medication. A flare 
was defined as an increase in total Likert pain score of 25% 
and $2, and a score of at least moderate on 1 or more of the   
5 items in the WOMAC pain subscale.
In both studies, exclusion criteria were secondary arthritis; 
previous major surgery; sensitivity to study treatment drugs 
or other NSAIDs; severe cardiac, renal, hepatic, or other 
systemic disease; and history of drug or alcohol abuse.
Treatment
Patients in the Tugwell et al study (n = 622) were treated with 
diclofenac topical solution (1.5% w/w diclofenac sodium, 
45.5% w/w DMSO, and other excipients) plus oral placebo 
capsules, or oral diclofenac 50-mg capsules plus topical 
placebo solution (2.3% w/w DMSO, no diclofenac). Patients 
applied 50 drops of study solution (approximately 1.55 mL) to 
the affected knee and took 1 study capsule, 3 times daily.13
In Simon et al, patients (n = 775) received one of 5   
treatments: 1) diclofenac topical solution (1.5% w/w 
diclofenac sodium, 45.5% w/w DMSO, plus other excipients) 
plus oral placebo tablets; 2) vehicle solution (45.5% w/w 
DMSO, no diclofenac) plus oral placebo tablets; 3) topical 
placebo solution (2.3% w/w DMSO, no diclofenac) plus 
oral placebo tablets; 4) placebo solution plus oral diclofenac 
tablets (100 mg, slow-release); or 5) diclofenac topical solu-
tion plus oral diclofenac tablets. Patients applied 40 drops of 
solution (approximately 1.2 mL) to the affected knee 4 times 
daily and took 1study tablet daily.14
Safety and efficacy assessments
Safety assessments in both studies included monitoring of 
AEs, recording of vital signs, dermatologic examination 
of the study knee (in patients in whom both knees were 
affected by OA, only the knee with the greater pain score 
at baseline was assessed), and clinical laboratory evalu-
ation (hematology, clinical chemistry, and urinalysis).13,14   
In addition, patients in the study by Simon et al underwent Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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ocular examination (visual acuity testing, slit lamp 
examination, and lens assessment) at baseline and the 
final visit.14
The 3 co-primary efficacy measures in both studies were 
changes from baseline in scores for the WOMAC pain and 
physical function subscales, and patient-evaluated efficacy 
(PGA in the Tugwell et al study13 and POHA in the Simon 
et al study14). Details on these co-primary efficacy assess-
ments, as well as secondary efficacy measures, have been 
previously published.13,14
statistical analysis
Differences in baseline demographic characteristics and 
the incidence of AEs between patients receiving diclofenac 
topical solution or oral diclofenac were analyzed by Chi-
square test or Fisher’s exact test for categorical variables, 
or by analysis of variance (ANOVA) with treatment as 
main effect for continuous variables. Descriptive statistics 
were provided for every safety variable, including mean, 
standard deviation, minimum and maximum for continuous 
variables (eg, vital signs), and incidence rate for noncon-
tinuous variables (eg, AEs). Where statistical tests were 
performed, they were 2-sided at the 5% level of significance 
(P , 0.05).
AEs were evaluated for statistical significance by system 
organ class (SOC). An AE was evaluated individually within 
a specific SOC if it showed a significant difference in occur-
rence of AEs between treatment groups. Additionally, an a 
priori analysis of individual AEs was initiated for several 
SOCs despite significance, including cardiovascular disor-
ders (hypertension, myocardial infarction, and cardiovascular 
death), gastrointestinal disorders (abdominal pain, diarrhea, 
dyspepsia, nausea, vomiting, halitosis, and body odor), and 
application-site conditions (contact dermatitis, dry skin, 
paresthesia, rash, and pruritus). These were analyzed due to 
their importance in oral and topical NSAID administration.   
Table 1 summary of study designs
Tugwell et al13 Simon et al14
Design Randomized, prospective, double-blind,  
double-dummy, active-controlled
Randomized, prospective, double-blind,  
double-dummy, placebo-, vehicle-,  
and active-controlled
setting 41 outpatient centers in canada 40 outpatient centers in canada;  
21 centers in the United states
Patients 622 patients (266 men, 356 women) with  
symptomatic, primary OA of the knee
775 patients (295 men, 480 women) with 
symptomatic, primary OA of the knee
inclusion criteria •   Recent (within 3 mo) radiographic  
evidence of knee OA
•   WOMAc pain subscale  
scorea $125 mm
•   WOMAc physical function subscale  
scorea $425 mm
• PgA scoreb $25 mm
•   Recent (within 3 mo) radiographic  
evidence of knee OA
•   Pain necessitating regular ($3 d/wk  
during the previous month) use of  
nsAiDs or other analgesics
•   WOMAc pain dimensional total  
score of $8, with flaresc
Treatment  
(duration, 12 wk)
•   Diclofenac topical solution  
(50 drops, 3 times daily)
•   Oral diclofenac capsules  
(50 mg, 3 times daily)
•   Diclofenac topical solution 
(40 drops, 4 times daily)
•   Oral diclofenac capsules  
(100 mg, once daily)
•   Placebo solution  
(2.3% w/w DMsO)
•   DMsO vehicle  
(45.5% DMsO)
•   Diclofenac topical solution + oral diclofenac
safety assessments Adverse event monitoring; vital sign  
measurements; dermatologic examination 
of study knee; clinical laboratory evaluation
Adverse event monitoring; vital sign measurements; 
dermatologic examination of study knee;  
clinical laboratory evaluation; ocular examination
co-primary  
efficacy endpoints
1.   WOMAc pain subscalea 
2.   WOMAc physical function subscalea 
3.   PgAb
1.   WOMAc pain subscaled 
2.   WOMAc physical function subscaled 
3.   POhAe
Notes: aUsing a VAs anchored from none (0 mm) to extreme (100 mm); bUsing a VAs anchored from very good (0 mm) to very poor (100 mm); cUsing the 5-item WOMAc 
OA Index pain dimension with each item scored 0–4 and a maximum score of 20. A flare was defined as pain after the washout of prior therapy that attained a score of $2 
(moderate) on at least one of the 5 items at baseline, or an increase in WOMAc pain total score from screening to baseline of $25% and $2; dUsing a 5-point scale anchored 
from none (0) to extreme (4); eUsing a 5-point scale anchored from very good (0) to very poor (4).
Abbreviations: DMSO, dimethyl sulfoxide; NSAID, nonsteroidal anti-inflammatory drug; OA, osteoarthritis; PGA, Patient Global Assessment; POHA, Patient Overall 
health Assessment; WOMAc, Western Ontario and McMaster Universities Osteoarthritis index; VAs, visual analog scale.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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If a category was statistically significant as a whole, the spe-
cific AEs within the group were evaluated for significance.
Results
A total of 927 patients was analyzed; 465 received diclofenac 
topical solution and 462 received oral diclofenac. Base-
line demographic characteristics for each study have been 
reported previously.13,14 There were no significant differ-
ences in baseline characteristics between treatment groups.
safety and tolerability
Treatment-emergent AEs occurred in 67.1% of patients 
receiving diclofenac topical solution and 64.5% taking 
oral diclofenac. The most common events occurring with 
diclofenac topical solution that occurred at a greater rate 
than with oral diclofenac were application site-related 
events. AEs leading to discontinuation occurred in 18.5% 
of patients receiving diclofenac topical solution and 21.0% 
receiving oral diclofenac. The most common AEs leading 
to discontinuation in the diclofenac topical solution group 
were application site-related events, whereas gastrointestinal 
disorders were the most common cause of discontinuation in 
the oral diclofenac group. Overall incidence of AEs for each 
SOC and incidence of individual treatment-emergent events 
and discontinuations are described in detail for each AE 
category, as well as AEs related to liver and renal function,   
vital signs, and musculoskeletal disorders.
gastrointestinal adverse events
Gastrointestinal AEs were significantly more common with 
oral diclofenac versus diclofenac topical solution (39.0% 
vs 25.4%, P , 0.0001). The most common gastrointestinal 
AEs were dyspepsia (18.4% vs 11.0%, P = 0.001), diarrhea 
(13.4% vs 6.5%, P , 0.001), abdominal distension (10.6% vs 
6.0%, P = 0.01), and abdominal pain upper (12.1% vs 5.6%, 
P , 0.001). Nonsignificant differences between groups were 
also shown for nausea (9.3% vs 5.2%), constipation (7.4% vs 
5.2%) and abdominal pain lower (5.4% vs 3.9%) (Table 2). 
A total of 67 patients (14.5%) receiving oral diclofenac 
and 27 patients (5.8%) receiving diclofenac topical solu-
tion discontinued because of a gastrointestinal-related AEs   
(P , 0.0001). One serious gastrointestinal AE was reported: 
gastric ulcer hemorrhage in 1 patient (0.2%) receiving oral 
diclofenac (Table 3).
cardiovascular adverse events
The incidence of cardiovascular AEs was low overall but 
was numerically higher in the oral diclofenac group, show-
ing a trend towards significance (3.5% vs 1.5%, P = 0.055). 
Differences between groups for all individual events (eg, 
hypertension, arrhythmia, and myocardial infarction) were 
nonsignificant and occurred in ,2% of individuals in either 
treatment group (Table 4). Four patients (0.9%) taking oral 
diclofenac and 1 patient (0.2%) taking diclofenac topical 
solution discontinued the study due to a cardiovascular   
Table 2 incidence of treatment-emergent gastrointestinal adverse events occurring in .1 patient in either treatment group
Adverse event, n (%) Diclofenac topical solution 
(n = 465)
Oral diclofenac  
(n = 462)
P value
Any gastrointestinal disorder 118 (25.4) 180 (39.0) ,0.0001*
Dyspepsia 51 (11.0) 85 (18.4) 0.001*
Diarrhea 30 (6.5) 62 (13.4) 0.0004*
Abdominal distension 28 (6.0) 49 (10.6) 0.01*
Abdominal pain upper 26 (5.6) 56 (12.1) 0.0005*
constipation 24 (5.2) 34 (7.4) 0.17*
nausea 24 (5.2) 43 (9.3) 0.15*
Abdominal pain lower 18 (3.9) 25 (5.4) 0.26*
Flatulence 8 (1.7) 9 (1.9) 0.80*
Abdominal pain 5 (1.1) 12 (2.6) 0.08*
Feces discolored 5 (1.1) 6 (1.3) 0.75*
Vomiting 5 (1.1) 9 (1.9) 0.28*
Breath odor 4 (0.9) 1 (0.2) 0.37†
Abdominal discomfort 3 (0.6) 8 (1.7) 0.13*
Dry mouth 3 (0.6) 1 (0.2) 0.62†
eructation 3 (0.6) 4 (0.9) 0.72†
epigastric discomfort 1 (0.2) 2 (0.4) 0.62†
gastrointestinal disorder 0 (0.0) 2 (0.4) 0.25†
hematochezia 0 (0.0) 2 (0.4) 0.25†
Toothache 0 (0.0) 2 (0.4) 0.25†
Notes: *From chi-square test; †From Fisher’s exact test.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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AE (P = 0.22). Three serious cardiovascular AEs were 
reported in 2 patients (0.4%) taking oral diclofenac: myo-
cardial infarction (n = 2) and coronary artery disease (n = 1) 
(Table 3). One of these patients died from stroke following 
the presentation of the cardiac event. One case of arterioscle-
rosis was observed in 1 patient receiving diclofenac topical 
solution, deemed as unrelated to treatment.
Application site-related adverse events
Application site-related AEs were significantly more common 
in patients receiving diclofenac topical solution than those 
receiving oral diclofenac (29.0% vs 6.1%, P , 0.0001). 
Dry skin (24.1% vs 1.9%, P , 0.0001), pruritus (4.9% vs 
1.9%, P = 0.01), and contact dermatitis (4.3% vs 0.6%,   
P , 0.001) were most common (Table 5). There was no dif-
ference between groups in paresthesia (both 1.3%). More 
individuals treated with diclofenac topical solution (8.8%) 
versus those receiving oral diclofenac (0.2%) discontinued 
due to an application-site reaction. There were no serious 
application site-related AEs in either group.
Liver and renal function
Compared with diclofenac topical solution, oral diclofenac 
was associated with significantly greater increases in liver 
enzymes and creatinine, and greater decreases in creatinine 
clearance and hemoglobin (Figure 1). At baseline, there were 
no significant differences in the incidence of abnormal liver 
enzyme concentrations between groups. However, at the 
end of the study, patients receiving oral diclofenac showed 
a significantly higher incidence of abnormal alanine amin-
otransferase (ALT) (22.2% vs 10.4%, P , 0.0001), aspar-
tate aminotransferase (14.6% vs 7.0%, P , 0.001), and 
g-glutamyltransferase (33.4% vs 21.1%, P , 0.0001). 
Additionally, there was a higher incidence of clinically 
significant elevations in ALT with oral diclofenac (4.1% vs 
1.2%, P , 0.01) (Table 6). Nonsignificant differences   
Table 3 incidence of serious adverse events
Diclofenac topical solution (n = 465) Oral diclofenac (n = 462)
Patients, n (%) Events, n Patients, n (%) Events, n
Any serious adverse events 1 (0.2) 1 6 (1.3) 8*
Vascular disorders
Arteriosclerosis 1 (0.2) 1 0 (0.0) 0
Cardiac disorders
Overall 0 (0.0) 0 2 (0.4) 3
Acute myocardial infarction 0 (0.0) 0 1 (0.2) 1
coronary artery disease 0 (0.0) 0 1 (0.2) 1
Myocardial infarction 0 (0.0) 0 1 (0.2) 1
Gastrointestinal disorders
gastric ulcer hemorrhage 0 (0.0) 0 1 (0.2) 1
Injury, poisoning, and procedural complications
Postprocedural hemorrhage 0 (0.0) 0 1 (0.2) 1
investigations
Liver function test abnormal 0 (0.0) 0 1 (0.2) 1
Musculoskeletal and connective tissue disorders
synovial cyst 0 (0.0) 0 1 (0.2) 1
Nervous system disorders
cerebrovascular accident 0 (0.0) 0 1 (0.2) 1
Notes: *From Fisher’s exact test, P = 0.069.
Table 4 incidence of treatment-emergent cardiovascular events
Adverse event, n (%) Diclofenac topical 
solution (n = 465)
Oral diclofenac 
(n = 462)
Any cardiovascular-related 
adverse event
7 (1.5) 16 (3.5)*
Vascular disorders
Overall 6 (1.3) 10 (2.2)
hypertension 5 (1.1) 8 (1.7)
Arteriosclerosis 1 (0.2) 0 (0.0)
Varicose veins 1 (0.2) 0 (0.0)
Hot flush 0 (0.0) 2 (0.4)
Cardiac disorders
Overall 1 (0.2) 6 (1.3)
Angina pectoris 1 (0.2) 0 (0.0)
  Acute myocardial infarction 0 (0.0) 1 (0.2)
Angina unstable 0 (0.0) 1 (0.2)
Arrhythmia 0 (0.0) 1 (0.2)
coronary artery disease 0 (0.0) 1 (0.2)
Myocardial infarction 0 (0.0) 1 (0.2)
Palpitations 0 (0.0) 2 (0.4)
  supraventricular  
extrasystoles
0 (0.0) 1 (0.2)
Notes: *From chi-square test, P = 0.055.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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between groups were shown for increases in serum creatinine 
(10.3% vs 8.2%, P = 0.30), as well as decreases in creatinine 
clearance (84.2% vs 81.3%, P = 0.36) and hemoglobin (9.8% 
vs 8.2%, P = 0.42) in the oral diclofenac and diclofenac 
topical solution groups, respectively. Discontinuation due 
to abnormal liver and renal function test results occurred in 
6 patients: 5 (1.1%) receiving oral diclofenac and 1 (0.2%) 
treated with diclofenac topical solution.
Vital signs
There were no significant differences between treatments in 
changes in mean blood pressure, heart rate, or respiratory 
rate. Patients treated with diclofenac topical solution had a 
mean (SD) change in systolic blood pressure and diastolic 
blood pressure (SBP/DBP) of −0.11 (12.55)/−0.27 (8.31) 
mm Hg versus a change of 0.34 (14.93)/−0.15 (9.20) mm 
Hg in patients receiving oral diclofenac. However, at the 
end of the study, the proportion of patients with abnormally 
elevated diastolic blood pressure values ($90 mm Hg) was 
significantly greater for oral diclofenac versus diclofenac 
topical solution (44.3% vs 34.9%, P , 0.01); there was no 
significant difference in the incidence of elevated systolic 
blood pressure values ($140 mm Hg) (Table 7).
Musculoskeletal
The most commonly reported musculoskeletal or connective 
tissue disorders were back pain, which occurred in a slightly 
higher proportion of patients treated with diclofenac topical 
solution (4.7%) versus those taking oral diclofenac (3.2%), 
and arthralgia, which occurred in slightly more patients tak-
ing oral diclofenac (4.8% vs 4.7%). The only nervous system 
disorder reported in .5% of patients in either group was 
headache (10.0% with oral diclofenac vs 8.8% with diclofenac 
topical solution). Thirteen patients in the diclofenac topical 
solution group (2.8%) discontinued due to musculoskel-
etal or connective tissue disorders, versus 6 patients taking 
oral diclofenac (1.3%). One musculoskeletal AE attributed to 
oral diclofenac, a synovial cyst, was considered serious.
Table 5 incidence of treatment-emergent application site-related adverse events
Adverse event, n (%) Diclofenac topical solution (n = 465) Oral diclofenac (n = 462) P value
Any application site-related adverse event 135 (29.0) 28 (6.1) ,0.0001*
Skin and subcutaneous tissue disorders
Overall 134 (28.8) 23 (5.0) ,0.0001*
Dry skin 112 (24.1) 9 (1.9) ,0.0001*
Pruritus 23 (4.9) 9 (1.9) 0.01†
Dermatitis contact 20 (4.3) 3 (0.6) 0.0004†
Rash 10 (2.2) 6 (1.3) 0.32
Urticaria 2 (0.4) 2 (0.4) .0.99
Nervous system disorders
Paresthesia 6 (1.3) 6 (1.3) 1.0
Notes: *From chi-square test; †From Fisher’s exact test.
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Figure 1 Mean changes in clinical chemistry measurements in patients receiving topical diclofenac solution or oral diclofenac.
Note: P , 0.0001 for all treatment differences except for creatinine clearance, where P , 0.001.
Abbreviations: ALT, alanine aminotransferase; AsT, aspartate aminotransferase; ggT, g-glutamyltransferase.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Discussion
The results in this pooled analysis confirm that NSAID-
related AEs remain a serious issue for OA patients. For 
example, NSAID gastropathy, nearly a quarter century after 
its identification, persists in the elderly who are at high risk 
for gastrointestinal events. Although two classes of medica-
tions, proton pump inhibitors and prostaglandins (misopros-
tol), have shown promise, treating NSAID gastropathy is 
problematic due to its asymptomatic nature and adherence 
challenges.6,17
Diclofenac topical solution was associated with a lower 
incidence of gastrointestinal AEs than the oral formulation. 
Dyspepsia, diarrhea, abdominal distention, abdominal pain, 
and nausea – all elements of NSAID gastropathy – were 
reported significantly more frequently with oral diclofenac 
treatment, including one serious gastrointestinal bleed-
ing event. In the current analysis, the incidence of peptic 
ulceration or gastrointestinal hemorrhage was low, and such 
events were confined to patients receiving oral diclofenac. 
The incidence rates of gastrointestinal AEs in patients taking 
oral diclofenac in this pooled analysis are consistent with 
previous studies (up to 48%); as well as discontinuation 
rates (up to 16%).18
While cyclooxygenase-2 (COX-2) selective NSAIDs 
are known for their reduced gastrointestinal effects, recent 
studies demonstrated significantly increased risk of cardio-
vascular events associated with these agents. This increased 
risk was first seen in rofecoxib during the VIGOR trial, 
which showed a significant increase in myocardial infarction 
compared with the nonselective NSAID naproxen (0.4% 
vs 0.1%, P , 0.05).19 These results were confirmed during 
the Adenomatous Polyp Prevention on VIOXX (APPROVe) 
trial, which showed a significant increase in cardiovascular 
events, including myocardial infarction, with rofecoxib com-
pared with placebo (2.4% vs 0.9%; hazard ratio 2.80 [95% 
CI 1.44–5.45]).20 These and other data led to withdrawal of 
rofecoxib from the market in 2005. One recent meta-analysis 
confirmed that rofecoxib is associated with increased car-
diovascular events (relative risk 1.24 [95% CI 1.05–1.46]) 
without evidence of similar increased risk with other COX-2 
selective agents such as celecoxib (relative risk 0.99 [95% 
CI 0.85–1.16]).21
The most common AEs with diclofenac topical solution 
in this analysis were application-site reactions. The incidence 
of application-site reactions in this study (29.0%) was greater 
than in recent studies of diclofenac sodium gel (5%–6% 
incidence)22,23 but was similar to that observed in previous 
placebo-controlled trials of diclofenac topical solution.10–12 
In the Simon et al study,14 which included a DMSO vehicle 
group, dry skin reaction incidence was similar between patients 
receiving the vehicle alone (11.2%) and diclofenac topical 
solution (18.2%), suggesting that these reactions are attribut-
able to the vehicle rather than the active drug. DMSO may 
produce skin dryness by dissolving lipids on the skin surface.14 
Although the effects of emollient use on application site-related 
AEs were not evaluated in the current analysis, it would likely 
help alleviate these reactions in clinical practice.
Abnormalities in hepatic and renal function are another 
concern with long-term oral NSAID therapy. At the end of 
the study, the incidence of abnormal liver enzyme elevations, 
particularly clinically significant elevations in ALT, was sig-
nificantly higher in patients who received oral diclofenac than 
Table 6 incidence of abnormal liver enzymes
  Diclofenac topical 
solution (n = 465)
Oral diclofenac (n 
= 462)
P value 
Any abnormality, n (%)
ALT
  Baseline 50 (10.9) 43 (9.5) 0.46*
  end of study 44 (10.4) 93 (22.2) ,0.0001*
AsT
  Baseline 40 (8.7) 29 (6.4) 0.18*
  end of study 30 (7.0) 61 (14.6) 0.0004*
ggT
  Baseline 108 (23.6) 106 (23.2) 0.90*
  end of study 90 (21.1) 140 (33.4) ,0.0001*
Clinically significant abnormalities, n (%)
ALT
  Baseline 4 (0.9) 3 (0.7) .0.99†
  end of study 5 (1.2) 17 (4.1) 0.009*
AsT
  Baseline 3 (0.7) 1 (0.2) 0.62†
  end of study 3 (0.7) 6 (1.4) 0.34†
ggT
  Baseline 14 (3.1) 10 (2.2) 0.41*
  end of study 18 (4.2) 22 (5.3) 0.48*
Notes: *From chi-square test; †From Fisher’s exact test.
Abbreviations: ALT, alanine aminotransferase; AsT, aspartate aminotransferase; 
ggT, g-glutamyltransferase.
Table 7 incidence of abnormally high blood pressure values
Patients with abnormal values P value
Diclofenac topical 
solution (n = 465)
Oral diclofenac (n 
= 462)
Diastolic blood pressure, n (%)
Baseline 178 (38.5) 206 (44.7) 0.058*
end of study 134 (34.9) 167 (44.3) 0.008*
Systolic blood pressure, n (%)
Baseline 353 (76.2) 356 (77.2) 0.72*
end of study 293 (76.3) 289 (76.7) 0.91*
Note: *From chi-square test.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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in those who were treated with diclofenac topical solution. 
Diclofenac topical solution did not show similar increases, 
which is likely due to reduced systemic levels with topical 
NSAIDs. Both groups, however, exhibited increased serum 
creatinine and decreased creatinine clearance, though the 
differences were not significant. These results may be 
related to the study populations, which had mean age of .60 
years. Decreased liver metabolism and renal excretion are 
2 pharmacologic attributes that can change as patients age, 
resulting in decreased oxidation in the liver and decreased 
renal excretion.24
The improved safety and tolerability profile of diclofenac 
topical solution, taken in context with similar improvements in 
efficacy versus oral diclofenac, highlight the potential impact 
of diclofenac topical solution in the overall treatment of OA. 
Nonselective oral NSAIDs, although generally well tolerated, 
are associated with increased risk of serious gastrointestinal and 
cardiovascular AEs.4 COX-2 inhibitors are associated with less 
gastrointestinal risk (although this risk is not completely miti-
gated) but greater cardiovascular risk compared with nonselec-
tive NSAIDs.4 US clinical guidelines recommend that patients 
be selected carefully after evaluating the risk of gastrointestinal, 
cardiovascular, and renal events, using particular caution in 
older patients.24 Those at increased gastrointestinal risk should 
receive a gastroprotective agent such as a proton pump inhibi-
tor in conjunction with oral nonselective NSAID therapy or 
be treated with COX-2 selective NSAIDs in the absence of 
pre-existing cardiovascular risk. Because OA most commonly 
occurs in older individuals, topical therapy is appropriate in 
these individuals, who have an inherently higher risk.24
In 2008, the United Kingdom-based National Institute for 
Health and Clinical Excellence (NICE) went a step further 
by recommending that topical NSAIDs, along with acet-
aminophen, should be the first pharmacologic options in the 
management of OA pain prior to the use of opioid analgesics, 
oral NSAIDS, and COX-2 inhibitors.3 US guidelines, such as 
the American College of Rheumatology guidelines (updated 
in 2000) and American Geriatrics Society guidelines (updated 
in 2009) have yet to include topical NSAIDs as first-line 
treatment.24 As more information concerning the safety and 
overall efficacy of topical NSAIDs is published and medical 
societies update their existing recommendations, health orga-
nizations will have new opportunities to evaluate these data.
Although efficacy data were not pooled for this analysis, in 
both current studies the efficacy of diclofenac topical solution 
was either equivalent or not significantly different from that of 
oral diclofenac. In Tugwell et al, the 95% confidence intervals 
for the treatment differences in WOMAC pain, WOMAC 
physical function, and PGA between diclofenac topical 
solution and oral diclofenac were all within the pre-defined 
equivalence ranges.13 In Simon et al, diclofenac topical solution 
produced significantly greater improvements in the co-primary 
endpoints of WOMAC pain, WOMAC physical function, and 
POHA compared with placebo or vehicle treatment, and was 
not significantly different from oral diclofenac.14
Limitations
While the information presented in this pooled analysis may 
be informative for guiding the overall management in OA, 
there were several limitations to consider. These trials were 
conducted over a period of 12 weeks, which may not be long 
enough to determine significant differences in AEs associated 
with long-term NSAID therapy, particularly cardiovascular 
AEs. Furthermore, these trials limited co-morbid conditions, 
concomitant medications, and the maximum doses of both 
oral diclofenac and diclofenac topical solution, all of which 
may affect the generalizability of these results. Additionally, 
since the 3 co-primary endpoints in both trials were assessed 
using different scales (visual analog pain scale for Tugwell et 
al,13 Likert scale for Simon et al14) it is not possible to pool 
the results from the WOMAC pain and physical function 
scales. Hence, only the safety data from these trials were 
pooled and reported here. Larger head-to-head, multicenter 
trials of much longer duration and that include a greater 
number of older patients are needed to adequately establish 
differences in long-term efficacy and safety between topical 
and oral formulations of diclofenac. It is possible that the 
results of the pooled analysis underestimate the compara-
tive clinical benefit of topical diclofenac solution over oral 
diclofenac for reducing the risks of serious gastrointestinal 
and cardiovascular AEs, especially for long-term treatment 
of OA in an elderly patient population of $75 years of age.
Conclusion
In conclusion, the pooled safety data from these 2 random-
ized trials demonstrated that diclofenac topical solution had 
a better tolerability profile than oral diclofenac, in terms 
of gastrointestinal AEs and changes in clinical laboratory 
variables. Because both studies showed that diclofenac topi-
cal solution was comparable in efficacy to oral diclofenac, 
these findings suggest that topical administration represents 
a useful alternative to oral treatment in the management of 
OA, especially in elderly patients and those at increased risk 
for serious gastrointestinal adverse events.Journal of Pain Research
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